MH Medications Lecture Notes

A set of flashcards covering key medications, concepts, and treatment protocols related to Malignant Hyperthermia, focusing on Dantrolene and Ryanodex.

Malignant Hyperthermia (MH)

A life-threatening condition triggered by certain anesthetics that leads to a rapid increase in body temperature and severe muscle contractions.

Dantrolene Sodium (Dantrium)

The primary medication used to treat Malignant Hyperthermia, working by preventing calcium release from muscle stores.

Ryanodex

A highly concentrated version of Dantrolene that simplifies administration and requires less volume of sterile water.

Initial Dose Calculation

For a 70 kg patient, the initial dose of Dantrolene calculated is 2.5 mg/kg, totaling 175 mg or 4 mL of Ryanodex.

Shelf Life of Ryanodex

Ryanodex has a shelf life of 2 years.

Shelf Life of Dantrium

Dantrium has a shelf life of 3 years.

Reconstitution of Dantrolene

Involves mixing Dantrolene with sterile water without a bacteriostatic agent and shaking to ensure a uniform suspension.

Signs of Malignant Hyperthermia

Elevated intercellular calcium levels and subsequent body temperature rise during or after anesthesia.

Administration of Dantrolene

Should be via intravenous push and can be repeated every 10-15 minutes as needed.

Team Management during MH Crisis

Involves coordinated roles including collecting medications, setting up arterial lines, and managing patient cooling.